Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Incidence: Occurs in around 9.1% (mean incidence of pooled analysis) of patients and is more common in men than in women [4]. Incidence is highest with combination therapy and is higher with CTLA4 inhibitor monotherapy than anti-PD-1 or –PD-L1 monotherapy [2].  The incidence of secondary adrenal insufficiency, secondary hypothyroidism and secondary hypogonadism were 6.1%, 7.6% and 7.5%, respectively [4].

Onset: Can present as early as week 4 post initiation of ICI and as late as week 16 [4].